1-5 of 5
Gerardo Capo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis

Free
Hanzala Jehangir, Sara Sharif, Muhammad Arham, Muhammad Uzair, Manzer Ali, Hamza Hameed, Iman Ali, Zahra Ali, Aleena Sharif, Haziq Ahmad, Gerardo Capo
Journal: Blood
Blood (2025) 146 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2025-1901
Published: 2025
Journal Articles

Racial disparities in lymphoma: Meta-analytic insights into diagnosis and survival gaps

Free
Hanzala Jehangir, Muhammad Arham, Muhammad Uzair, Manzer Ali, Hamza Hameed, Usman Mazhar, Adil Ahmed, Umer Nasir, Gerardo Capo, Mersiha Hadziahmetovic, Hammad Rashid
Journal: Blood
Blood (2025) 146 (Supplement 1): 8054.
https://doi.org/10.1182/blood-2025-8054
Published: 2025
Journal Articles

Bayesian diagnostic test accuracy meta-analysis of ¹⁸F-FDG PET/CT for detecting Richter's transformation in chronic lymphocytic leukemia

Free
Hanzala Jehangir, Muhammad Arham, Muhammad Uzair, Manzer Ali, Emaan Amjad, Rajesh Thirumaran, Farah Faridi, Gerardo Capo, Mersiha Hadziahmetovic
Journal: Blood
Blood (2025) 146 (Supplement 1): 7420.
https://doi.org/10.1182/blood-2025-7420
Published: 2025
Journal Articles

A Phase II Study of Bortezomib (Velcade ® ), Cyclophosphamide (Cytoxan ® ), Thalidomide (Thalomid ® ) and Dexamethasone as First-Line Therapy for Multiple Myeloma

Free
William Bensinger, Sundar Jagannath, MD, Robert Vescio, MD, Elber S. Camacho, MD, Jeffrey Lee Wolf, David H Irwin, MD, Gerardo Capo, III, MD, Marti McKinley, Phyllis Potts, David H. Vesole, MD, PhD, Amitabha Mazumder, MD, Dixie-Lee Esseltine, MD, Pamela Becker, John Crowley, PhD, Brian GM Durie, MD
Journal: Blood
Blood (2008) 112 (11): 94.
https://doi.org/10.1182/blood.V112.11.94.94
Published: 2008
Journal Articles

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Free
Sundar Jagannath, MD, Bill Bensinger, MD, Robert Vescio, MD, Elber Camacho, MD, Jeffrey Wolf, MD, David Irwin, MD, Gerardo Capo, MD, Marti McKinley, MD, David H. Vesole, MD, Amitabha Mazumder, MD, John Crowley, MD, Dixie Esseltine, MD, Brian Durie, MD
Journal: Blood
Blood (2007) 110 (11): 188.
https://doi.org/10.1182/blood.V110.11.188.188
Published: 2007